Amneal Pharmaceuticals, Inc. (AMRX) 当前追踪市盈率 (P/E) 为 55.1, 前瞻市盈率为 13.2. 追踪盈利收益率为 1.81%, 前瞻盈利收益率 7.59%. PEG 0.04 (Peter Lynch 低估标准 ≤1.0). 格雷厄姆数为 $0.31.
本页证实的标准:
SharesGrow 综合评分： 53/100 其中 2/7 项标准通过。
| Year | P/E (TTM) | PEG 比率 | P/B 比率 | P/S 比率 | 股息收益率 |
|---|---|---|---|---|---|
| 2016 | 12.1 | 0.54 | -13.52 | 2.46 | 8.01% |
| 2017 | 11.4 | 0.35 | -4.96 | 1.85 | 19.62% |
| 2018 | -10.1 | 0.05 | 1.92 | 1.04 | 10.63% |
| 2019 | -1.8 | -0.01 | 2.74 | 0.39 | - |
| 2020 | 7.5 | -0.07 | 2.25 | 0.34 | - |
| 2021 | 67.1 | -0.76 | 1.98 | 0.34 | - |
| 2022 | -2.3 | 0.00 | 1.01 | 0.14 | - |
| 2023 | -12.6 | 0.29 | 53.70 | 0.44 | - |
| 2024 | -20.9 | 1.00 | -22.40 | 0.88 | - |
| 2025 | 54.8 | -0.34 | -55.77 | 1.31 | - |
| Year | EPS（稀释） | 营收 | 净利润 | 净利润率 |
|---|---|---|---|---|
| 2016 | $1.81 | $1.02B | $207.38M | 20.4% |
| 2017 | $1.46 | $1.03B | $167.65M | 16.2% |
| 2018 | $-1.33 | $1.66B | $-169.73M | -10.2% |
| 2019 | $-4.57 | $1.63B | $-603.57M | -37.1% |
| 2020 | $0.61 | $1.99B | $91.06M | 4.6% |
| 2021 | $0.07 | $2.09B | $10.62M | 0.5% |
| 2022 | $-0.86 | $2.21B | $-129.99M | -5.9% |
| 2023 | $-0.48 | $2.39B | $-83.99M | -3.5% |
| 2024 | $-0.38 | $2.79B | $-116.89M | -4.2% |
| 2025 | $0.22 | $3.02B | $72.06M | 2.4% |
| Year | EPS（平均） | EPS 范围 | 营收（平均） | 营收范围 | 分析师人数 |
|---|---|---|---|---|---|
| 2026 | $0.99 | $0.98 – $1.00 | $3.09B | $3.07B – $3.1B | 3 |
| 2027 | $1.18 | $1.13 – $1.24 | $3.3B | $3.28B – $3.33B | 3 |
| 2028 | $1.37 | $1.36 – $1.39 | $3.5B | $3.5B – $3.5B | 1 |
